Editorial
doi: 10.1080/14787210.2016.1233060.
What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
Affiliations
- PMID: 27599088
- DOI: 10.1080/14787210.2016.1233060
Item in Clipboard
Editorial
What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
Expert Rev Anti Infect Ther.
2016 Oct.
No abstract available
Keywords: Ceftolozane/tazobactam; Enterobacteriaceae; Pseudomonas aeruginosa; carbapenem-sparing regimens; ceftazidime/avibactam; complicated intra-abdominal infections; complicated urinary tract infections; multidrug-resistance.
Similar articles
-
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.Antimicrob Agents Chemother. 2017 Sep 22;61(10):e00875-17. doi: 10.1128/AAC.00875-17. Print 2017 Oct. Antimicrob Agents Chemother. 2017. PMID: 28739780 Free PMC article.
-
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).Int J Antimicrob Agents. 2018 Feb;51(2):181-189. doi: 10.1016/j.ijantimicag.2017.09.016. Epub 2017 Oct 6. Int J Antimicrob Agents. 2018. PMID: 28993143
-
Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.J Antimicrob Chemother. 2018 Sep 1;73(9):2519-2523. doi: 10.1093/jac/dky204. J Antimicrob Chemother. 2018. PMID: 29912399 Clinical Trial.
-
Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.Int J Antimicrob Agents. 2015 Sep;46(3):266-71. doi: 10.1016/j.ijantimicag.2015.05.003. Epub 2015 Jun 14. Int J Antimicrob Agents. 2015. PMID: 26143591 Review.
-
Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.Ann Pharmacother. 2015 Sep;49(9):1046-56. doi: 10.1177/1060028015593293. Epub 2015 Jul 9. Ann Pharmacother. 2015. PMID: 26160970 Review.
Cited by
-
Ceftolozane/Tazobactam for Resistant Drugs Pseudomonas aeruginosa Respiratory Infections: A Systematic Literature Review of the Real-World Evidence.Life (Basel). 2021 May 24;11(6):474. doi: 10.3390/life11060474. Life (Basel). 2021. PMID: 34073847 Free PMC article. Review.
-
Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis.World J Hepatol. 2017 Oct 28;9(30):1166-1175. doi: 10.4254/wjh.v9.i30.1166. World J Hepatol. 2017. PMID: 29109849 Free PMC article. Review.
-
Escherichia coli producing AmpC DHA-1 bacteraemia in neutropenic leukemic patient: continuous infusion ceftazidime/avibactam as a carbapenem sparing regimen.JAC Antimicrob Resist. 2025 Jun 18;7(3):dlaf109. doi: 10.1093/jacamr/dlaf109. eCollection 2025 Jun. JAC Antimicrob Resist. 2025. PMID: 40583993 Free PMC article.
-
Cyclic Boronates Inhibit All Classes of β-Lactamases.Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02260-16. doi: 10.1128/AAC.02260-16. Print 2017 Apr. Antimicrob Agents Chemother. 2017. PMID: 28115348 Free PMC article.
-
New β-Lactam Antibiotics and Ceragenins - A Study to Assess Their Potential in Treatment of Infections Caused by Multidrug-Resistant Strains of Pseudomonas aeruginosa.Infect Drug Resist. 2021 Dec 25;14:5681-5698. doi: 10.2147/IDR.S338827. eCollection 2021. Infect Drug Resist. 2021. PMID: 34992394 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
